Clinical trials: Biological Therapy
Neoplasm
Evaluating Biobanking Educational Tools
The purpose of this study is to evaluate English and Spanish language educational materials that inform the community about a type of cancer research that involves the collection, storage, and processing of biospecimens.
- Trial name
- NCT01672944
- Testing
- TBCCN-developed educational materials, NCI-developed educational materials
- Where
- United States
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Crohn's Disease, IBD
Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
Crohn's disease and ulcerative colitis affect about 1.6 to 3 million people in the United States with many of those being young children and adolescents.
- Trial name
- ENvISION (NCT04131504)
- Testing
- Infliximab, Adalimumab
- Where
- 4 sites in United States
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Kidney Cancer
Vaccine Therapy in Treating Patients With Kidney Cancer
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00014131
- Testing
- Biological/Vaccine: therapeutic autologous dendritic cells.
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lisata Therapeutics, Inc.
Diabetic Autonomic Neuropathy
Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
The main objective is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes.
- Trial name
- NCT02682901
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Eastern Virginia Medical School
Renal Cell Carcinoma
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.
- Trial name
- NCT00678119
- Testing
- AGS-003, Sunitinib
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Argos Therapeutics
Hiatal Hernia
Biologic Versus Synthetic Mesh for Treatment of Paraesophageal Hernia
The investigators propose a randomized, single blinded controlled trial to compare the use of synthetic versus biologic mesh in hiatal hernia repair, two currently accepted standard of care surgical modalities.
- Trial name
- NCT02242526
- Testing
- Parietex™ Composite Hiatal Mesh, North Haven, CT, Biodesign™ Surgisis® Graft, Cook Medical, Bloomington
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Stony Brook University
Herpes Zoster
Shingrix in Patients With Rheumatic Diseases: a Double-blind Placebo-controlled RCT
A double-blind randomized controlled trial on the safety and immunogenicity of the recombinant subunit herpes zoster vaccine, Shingrix, in patients with rheumatic diseases undergoing immunosuppressive or biologic/targeted DMARD…
- Trial name
- NCT04748939
- Testing
- recombinant subunit herpes zoster vaccine
- Where
- China
- Sponsor
- Tuen Mun Hospital
Rheumatoid Arthritis
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent
This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active…
- Trial name
- ACT-MOVE (NCT02046603)
- Testing
- Tocilizumab, DMARDs, Oral Corticosteroids
- Where
- 38 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Chronic Plaque Psoriasis
Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial
The goal of this clinical trial is to learn if Infliximab Biosimilar Remsima works to treat moderate to severe plaque Psoriasis in adults. It will also learn about the safety of the drug.
- Trial name
- NCT06591273
- Testing
- Infliximab-dyyb Biosimilar (Remsima)
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Ulcerative Colitis
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon characterized by superficial mucosal inflammation. Treatment aims to achieve and maintain remission, improve quality of life, and minimize complications.
- Trial name
- BOOST-UC (NCT06906445)
- Testing
- Fecal Microbial Transplantation, Anti-Inflammatory Diet, Advanced Therapy
- Where
- 6 sites in India
- Volunteers
- 220 people
- Sponsor
- All India Institute of Medical Sciences
Prostate Cancer
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.
- Trial name
- NCT00065442
- Testing
- Sipuleucel-T
- Where
- 71 sites in United States, Canada
- Volunteers
- 512 people
- Sponsor
- Dendreon
Rectal Cancer
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1.
- Trial name
- CEA+RC-BCG (NCT02403505)
- Testing
- CEA protein antigen plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Rheumatoid Arthritis
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
This study was an extension to study MA21573 [NCT00750880], which was an open label single arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biological…
- Trial name
- NCT00883753
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 171 sites in Australia, Canada and 12 more
- Volunteers
- 934 people
- Sponsor
- Hoffmann-La Roche
Crohn's Disease
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo as induction therapy in participants with moderately and severely active Crohn's disease (CD).
- Trial name
- NCT03345836
- Testing
- Upadacitinib
- Where
- 428 sites in United States, Argentina and 46 more
- Volunteers
- 624 people
- Sponsor
- AbbVie
Knee Osteoarthritis
Phase 1b Clinical Trial to Evaluate PEP and EUFLEXXA for Knee Osteoarthritis (KOA)
Evaluate the safety and exploratory efficacy of single intra-articular injections of PEP reconstituted with 0.9% Normal Saline at a low dose (one vial PEP) and high dose (two vials PEP), with and without EUFLEXXA, for the…
- Trial name
- NCT06463132
- Testing
- PEP/Euflexxa, PEP
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rion Inc.
Breast Cancer, Cancer Survivor
Fatigue in Breast Cancer Survivors
RATIONALE: Gathering information over time from blood samples and measurements of activity, sleep, mood, and cognition may help doctors learn more about fatigue in breast cancer survivors and plan the best treatment.
- Conditions
- Breast Cancer, Cancer Survivor, Fatigue, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00972400
- Testing
- protein analysis, laboratory biomarker analysis, mass spectrometry
- Where
- United Kingdom
- Volunteers
- 96 people
- Sponsor
- St George's, University of London
Personality Disorders
Biological Effects of Schema Therapy
Background: The major aim of this study is to compare the effects of emotion focused (experiential) and cognitive interventions of schema therapy (ST) on emotion regulation deficits in patients with borderline personality…
- Trial name
- BE-ST (NCT06367907)
- Testing
- schema therapy
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Jena University Hospital
Lymphoma
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004198
- Testing
- keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy
- Where
- United States
- Sponsor
- University of Nebraska
Ankylosing Spondylitis
Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis
This study is to evaluate available data in Iraqi patients with ankylosing spondylitis on Enbrel treatment with regards to the impact of early treatment using data from the Baghdad Teaching Hospital registry
- Trial name
- NCT04507763
- Testing
- Etanercept
- Where
- Iraq
- Volunteers
- 763 people
- Sponsor
- Pfizer
Hairy Cell Leukemia
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Background: Hairy cell leukemia (HCL) is a rare, slow-growing blood cancer in which the bone marrow makes too many of certain white blood cells.
- Trial name
- NCT03805932
- Testing
- Moxetumomab Pasudotox-tdfk, Rituximab, Ruxience
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.